Bickel U, Born J, Fehm H L, Distler M, Voigt K H
Institut für Klinische Pharmakologie, Freie Universität Berlin, Federal Republic of Germany.
Eur J Clin Pharmacol. 1988;35(4):371-7. doi: 10.1007/BF00561367.
A specific radioimmunoassay for the quantitative measurement of ACTH 4-10 and a procedure for its extraction from plasma have been developed. Its pharmacokinetics was studied in eight healthy male volunteers given ACTH 4-10 125 micrograms/kg body weight as a bolus i.v. injection, by infusion and intranasally. Following the i.v. bolus, plasma levels rapidly declined biexponentially, with half-lives of 0.39 +/- 0.05 min for the alpha-phase and 3.84 +/- 1.5 min for the beta-phase (mean +/- SD). The constant rate i.v. infusion yielded steady-state levels between 0.74 and 5.06 ng/ml plasma. Administered as intranasal spray, absorption of intact ACTH 4-10 was low and variable (maximal bioavailability 7.6%). The results are discussed in relation to the dose-dependent effects of ACTH 4-10 on the auditory evoked potential.
已开发出一种用于定量测定促肾上腺皮质激素4-10(ACTH 4-10)的特异性放射免疫分析法及其从血浆中提取的方法。在八名健康男性志愿者中,通过静脉推注、输注和鼻内给药的方式给予125微克/千克体重的ACTH 4-10,研究了其药代动力学。静脉推注后,血浆水平迅速呈双指数下降,α相半衰期为0.39±0.05分钟,β相半衰期为3.84±1.5分钟(平均值±标准差)。静脉恒速输注产生的稳态血浆水平在0.74至5.06纳克/毫升之间。以鼻喷雾剂给药时,完整的ACTH 4-10吸收较低且变化较大(最大生物利用度7.6%)。结合ACTH 4-10对听觉诱发电位的剂量依赖性效应讨论了研究结果。